banner medline tsn
МЕДЛАЙН.РУ
Содержание журнала

Архив

Редакция
Учредители

Федеральное государственное бюджетное учреждение науки
Институт теоретической и экспериментальной биофизики
Российской академии наук


ООО "ИЦ КОМКОН"

ФГБУН "Институт токсикологии" ФМБА России

Адрес редакции и реквизиты

192012, Санкт-Петербург, ул.Бабушкина, д.82 к.2, литера А, кв.378

Свидетельство о регистрации электронного периодического издания ЭЛ № ФС 77-37726 от 13.10.2009
Выдано - Роскомнадзор

ISSN 1999-6314


Клиническая медицина » Хирургия • Онкология, лучевая терапия

Том: 15
Статья: « 52 »
Страницы:. 649-671
Опубликована в журнале: 30 сентября 2014 г.
English version

Рак эндометрия: гетерогенность и генетические маркеры.

Чернобровкина А.Е., Свирин Н.А.

Государственное бюджетное учреждение здравоохранения «Санкт-Петербургский клинический научно-практический центр специализированных видов медицинской помощи (онкологический)».


Резюме
Проводится оценка молекулярно-генетического тестирования для определения прогностических и предиктивных характеристик различных генетических вариантов рака эндометрия. В последнее время решение этой проблемы во многом связывают с медико-генетическими исследованиями, направленными на изучение роли наследственной предрасположенности к развитию рака эндометрия и выявлению лиц с потенциально высоким риском заболевания. Все это подтверждает необходимость проведения дальнейшего изучения генетических основ рака эндометрия, которое позволит оптимизировать алгоритмы ранней диагностики, патогенетически обоснованной профилактики и лечебных мероприятий. Подводя итоги, следует признать, что мутационный фон рака эндометрия является комплексным, многофакторным и гетерогенным параметром не только между, но также и внутри каждого подтипа (I и II) РЭ. Необходимо подчеркнуть, что указанные в данном обзоре мутации в PIK3CA, PIK3R1, KRAS и PTEN не являются специфичными, и различные поломки и их взаимодействия с известными раковыми генами на пути разгадки. Более вдумчивое понимание, что первый и второй типы РЭ являются генетически отличительными друг от друга, будет шагом навстречу к совершенствованию будущих клинических испытаний.


Ключевые слова
рак эндометрия, PIK3CA, PIK3R1, KRAS, PTEN, MSI, EGFR


(статья в формате PDF. Для просмотра необходим Adobe Acrobat Reader)



открыть статью в новом окне

Список литературы

1. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, Peltomäki P, Mecklin JP, Järvinen HJ. Cancer risk in mutation carriers of DNA-mismatch-repair genes. // Int J Cancer. 1999; 81(2):214–218.


2. Akbay E, et al. Differential Roles of Telomere Attrition in Type I and II Endometrial Carcinogenesis. // American Journal of Pathology. –2008.–Vol. 173.–No. 2. –P. 536–544.


3. American Cancer Society. Cancer Facts & Figures 2013. // Atlanta: American Cancer Society; 2013.


4. An H, et al. Molecular characterization of uterine clear cell carcinoma. // Modern Pathology. –2004. – Vol. 17. –No. 5. –P. 530–537.


5. Baglietto L, Lindor NM, Dowty JG, White DM, Wagner A, Gomez Garcia EB, Vriends AH, Dutch Lynch Syndrome Study Group. Cartwright NR, Barnetson RA: Risks of Lynch syndrome cancers for MSH6 mutation carriers. // J Natl Cancer Inst. 2010; 102 (February (3)):193–201.


6. Banno K1, Kisu I, Yanokura M, Masuda K, Ueki A, Kobayashi Y, Susumu N, Aoki D.. Epigenetics and genetics in endometrial cancer: new carcinogenic mechanisms and relationship with clinical practice. // Epigenomics 2012. –No. 4(2). – P.147-62.


7. Banno K1, Kisu I, Yanokura M, Tsuji K, Masuda K, Ueki A, Kobayashi Y, Yamagami W, Nomura H, Tominaga E, Susumu N, Aoki D. et al. Biomarkers in endometrial cancer: Possible clinical applications (Review). // Oncology letters. 2012 Jun; 3(6):1175-1180.


8. Bansal N, et al. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies.// Cancer Control. –2009. –Vol. 16. –No. 1, –P. 8–13.


9. Basil, J. B., Goodfellow, P. J., Rader, J. S., Mutch, D. G. & Herzog, T. J. Clinical significance of microsatellite instability in endometrial carcinoma. // Cancer 89, 1758–1764 (2000).


10. Berstein L M, Imianitov E N, Gamaiunova V B, Kovalevskii Alu, Kuligina E Sh, Belogubova E V, Chernobrovkina A E. Genetic polymorphism of steroid 17 aipha-hydroxylase/17,20-lyase (CYP 17) and hyperinsulinemia in endometrial carcinoma.// Vopr Oncol. – 2002. – Vol 48(6). – P. 673-678.


11. Biscuola M1, Van de Vijver K, Castilla MÁ, Romero-Pérez L, López-García MÁ, Díaz-Martín J, Matias-Guiu X, Oliva E, Palacios Calvo J. Oncogene alterations in endometrial carcinosarcomas. // Human pathology.2013 May; 44(5):852-9.


12. Brembeck FH, Rosario M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. // Curr Opin Genet Dev 2006; 16:51–59.


13. Brown E.J., Albers M.W., Shin T.B. et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. // Nature. 1994. Vol. 369. P. 756–758


14. Casarotto A1, Cerofolini A, Landoni L, Contin F, Chiappetta A, Rebonato M. Inguinal endometriosis. Case report and review of the literature. // Il Giornale di chirurgia.. –2011; 32(4):199–202.


15. Chiu M.I., Katz H., Berlin V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. //Proc Natl Acad Sci USA. 1994. Vol. 91. P. 12574–12578


16. Choi YH, Cotterchio M, McKeown-Eyssen G, Neerav M, Bapat B, Boyd K, Gallinger S, McLaughlin J, Aronson M, Briollais L. Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario. // Hered Cancer Clin Pract. 2009;7 (August (1)):14.[PMC free article][PubMed]


17. Creutzberg CL1, Kitchener HC, Birrer MJ, Landoni F, Lu KH, Powell M, Aghajanian C, Edmondson R, Goodfellow PJ, Quinn M, Salvesen HB, Thomas G; GCIG Endometrial Cancer Clinical Trials Planning Meeting. Gynecologic Cancer InterGroup (GCIG) endometrial cancer clinical trials planning meeting: taking endometrial cancer trials into the translational era. // International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.2013 Oct; 23 (8):1528-34.


18. Davidson N.O. 2007. Genetic testing in colorectal cancer: who, when, how and why. // Keio J. Med. 56, 14–20.


19. Di Cristofano A, Ellenson LH. Endometrial carcinoma. // Annu Rev Pathol. 2007; 2:57–85.


20. Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, Liu B, Kinzler KW, Vogelstein B. Cancer risk associated with germline DNA mismatch repair gene mutations. // Hum Mol Genet. 1997; 6(1):105–110.


21. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. //Nat Rev Genet. 2006. Vol.7. P. 606–619


22. Evans D.G., Walsh S., Hill J., McMahon R.T. Strategies for identifying hereditary nonpolyposis colon cancer. // Semin. Oncol. 2007. 34, 411–417.


23. Fleming GF, Sill MW, Darcy KM, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. // Gynecol Oncol 2010; 116:15–20.


24. Gutierrez A., Sanda T., Grebliunaite R., Carracedo A., Salmena L., Ahn Y., Dahlberg S., Neuberg D., Moreau L.A., Winter S.S., Larson R., Zhang J. et al. High frequency of PTEN, PI3K and AKT abnormalities in T cell acute lymphoblastic leukemia. // Blood. 2009. Vol. 114. P. 647–650.


25. Hampel H, Stephens JA, Pukkala E, Sankila R, Aaltonen LA, Mecklin JP, de la Chapelle A. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. // Gastroenterology. 2005; 129(2):415–421. [PubMed: 16083698].


26. Häring J, Skrzypczak M, Stegerer A, et al. Estrogen receptor β transcript variants associate with oncogene expression in endometrial cancer. // International Journal of Molecular Medicine. 2012; 29(6):1127–1136.


27. Hayes MP, Wang H.,et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. // Clin. Cancer Res 2006; 12:5932-5935.


28. Hendriks YM, Wagner A, Morreau H, Menko F, Stormorken A, Quehenberger F, Sandkuijl L, Møller P, Genuardi M, Van Houwelingen H, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. // Gastroenterology. 2004;127 (1):17–25.[PubMed]


29. Holcomb K, Delatorre R, Pedemonte B, et al. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. // Obstet Gynecol 2002; 100:1290–1295.


30. Holcomb K. et al. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. // Obstet.Gynecol.100, 1290-1295 (2002).


31. International Agency for Research on Cancer and its work in producing GLOBOCAN 2008. Global Cancer Facts & Figures. // WHO (6/3/2011) – p. 3-7.


32. Jia L, Liu Y, Yi X, et al. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. // Clin Cancer Res 2008; 14:2263–2269.


33. Kaku T., Kamura T., Hirakawa T., et al. Study of amgiogenesis and p53 overexpression.// Gynecologic Oncology. –1999. –Vol. 72. –No. 1. – P. 51–55.


34. Kawaguchi M, Yanokura M, Banno K, et al. Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer. //Int J Oncol 2009; 34:1541–1547.


35. Kempers M. et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. // Lancet Oncol. 2011; 12: 49–55.


36. Kildal W1, Micci F, Risberg B, Abeler VM, Kristensen GB, Heim S, Danielsen HE. Genomic imbalances in endometrial adenocarcinomas - comparison of DNA ploidy, karyotyping and comparative genomic hybridization. // Molecular oncology.6 (1):98-107. - 2012.


37. Kimberly K. Leslie, Kristina W. Thiel, Donghai D. Da. The Estrogen Receptor Joins Other Cancer Biomarkers as a Predictor of Outcome. // Obstetrics and Gynecology International. 2013; 1-5.


38. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. Lynch Syndrome. American Society of Clinical Oncology. // Journal of clinical oncology : official journal of the American Society of Clinical Oncology.21(12):2397-406.- 2003.


39. Kudela M1, Pilka R, Lubusky M, Hejtmanek P, Dzubak P, Brychtova S. Prognostic importance of selected molecular immunohistochemical markers and DNA ploidy in endometrial cancer.. // European journal of gynaecological oncology. 33(2):159-63. – 2012.


40. Lax S et al. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. // Human Pathology. –1998. –Vol. 29 –No. 6. –P. 551–558.


41. Lax SF, Kendall B, Tashiro H, et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. // Cancer 2000; 88:814–824.


42. Le Gallo M, O'Hara AJ, Rudd ML, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. // Nature Genetics. 2012;44(12):1310–1315. 


43. Lee EJ, Kim TJ, Kim DS, et al. p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review. // Gynecol Oncol. 2010; 116:533–538.


44. Leslie KK, Sill MW, Darcy KM, et al. Efficacy and safety of gefitinib and potential prognostic value of soluble EGFR, EGFR mutations, and tumor markers in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. // J Clin Oncol 2009; 27 (Suppl): abstract 16542.


45. Levine RL, et al. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. // Cancer Res 1998; 58:3254-3258.


46. Liang H, Cheung LW, Li J, et al. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. // Genome Research. 2012; 22(11):2120–2129.


47. MacDonald, N. D. et al. Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas. // Cancer Res. 60, 1750–1752 (2000).


48. Machin P, Catasus L, Pons C, et al. CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. // Hum Pathol 2002; 33:206–212.


49. Maxwell GL, et al. Mutations of the PTEN tumor suppressor gene in endometrial hyperplasias. // Cancer Res 1998; 58:2500-2503.


50. Moreno-Bueno G, Hardisson D, Sanchez C, et al. Abnormalities of the APC/ beta-catenin pathway in endometrial cancer. // Oncogene 2002; 21:7981–7990.


51. Moreno-Dueno G. et al. Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. // J. Pathol. 199, 471-478 (2003).


52. Mutch DG, Powell MA, Mallon MA, et al. RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers. // Am J Obstet Gynecol. - 2004; 190:935–942.


53. Mutter GL, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. // J Nat| Cancer Inst 2000; 92:924-930.


54. N. Bansal, V. Yendluri, and R. M. Wenham. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies.// Cancer Control. –2009. –Vol. 16. –No. 1, –P. 8–13.


55. Oda K, et al. PIK3CA cooperates with other phosphatidylinositol 3-kinase pathway mutations to effect oncogenic transformation. // Cancer Res 2008; 68:8127-8136.


56. Ponz de Leon M. et al. Identification and classification of hereditary nonpolyposis colorectal cancer (Lynch syndrome): adapting old concepts to recent advancements. Report from the Italian Association for the study of Hereditary Colorectal Tumors Consensus Group. // Dis. Colon Rectum. 50, 2126–2134.


57. Ray-Coquard I1, Chauvin F, Leblanc E, Caux C, Hoarau H, Bonnetain F, Christophe V, Sastre-Garau X, Lazennec G, Poulain L, Haie-Meder C, Pujade-Lauraine E, Salzet M, Deutsch E, Devouassoux M, Penault Llorca F, Lecuru F, Taieb S, Arveux P, Theillet C, Joly F. PAIR-gynaecology: multi/interdisciplinary for gynecologic cancer research. Problems needed to be resolved. // Bull Cancer. 2012 Apr 1;99(4):479-98.


58. Rudd ML, et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res 2011; 17:1331-1340.


59. Sabers C.J., Martin M.M., Brunn G.J. et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.//J Biol Chem. 1995. Vol. 270. P. 815–822


60. Salvesen HB, Kumar R, Stefansson I, et al. Low frequency of BRAF and CDKN2A mutations in endometrial cancer. // Int J Cancer - 2005. 115:930–934.


61. Santin AD, Bellone S, Gokden M, et al. Overexpression of HER-2/neu in uterine serous papillary cancer. // Clin Cancer Res 2002; 8:1271–1279.


62. Schlosshauer PW, Ellenson LH, Soslow RA. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. // Mod Pathol 2002; 15:1032–1037.


63. Scholten AN, Creutzberg CL, van den Broek LJ, et al. Nuclear beta-catenin is a molecular feature of type I endometrial carcinoma. // J Pathol 2003; 201:460–465.


64. Stefansson IM, Salvesen HB, Akslen LA. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. // J Clin Oncol 2004; 22:1242–1252.


65. Stiles B.L. Phosphatase and tensin homologue deleted on chromosome 10: extending its PTENtacles. Int J Biochem //Cell Biol. 2009. Vol.41.P. 757–761


66. Tashiro H, Isacson C, Levine R, et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. // Am J Pathol. 1997; 150:177–185.


67. Vasen H.F. et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). // J. Med. Genet. 44, 353–362.


68. Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G, Nagengast FM, Meijers-Heijboer EH, Bertario L, Varesco L, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. // Gastroenterology. 1996; 110(4):1020–1027.


69. Vivanco I, et al. The phosphatidylinositol 3-kinase AKT pathway in human cancer. // Nat Rev Cancer 2002; 2:489-501.


70. Vousden KH, Lu X. Live or let die: the cell’s response to p53. // Nat Rev Cancer- 2002; 2:594–604.


71. Zhang Z1, Zhou D, Lai Y, Liu Y, Tao X, Wang Q, Zhao G, Gu H, Liao H, Zhu Y, Xi X, Feng Y. Estrogen induces endometrial cancer cell proliferation and invasion by regulating the fat mass and obesity-associated gene via PI3K/AKT and MAPK signaling pathways. // Cancer letters.– 2012. –No. 319(1). – P. 89-97.


72.  Zhao S, Choi M, Overton JD, et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. // Proceedings of the National Academy of Sciences of USA. 2013; 110(8):2916–2921.


73. Берштейн Л.М., Чернобровкина А.Е., Гамаюнова В.Б. и др. Активность ароматазы, тканевое содержание эстрогенов и особенности течения рака тела матки. // Вопр.онкол. –2003. –Т.49 (1). –С. 55-59.


74. Власов Р.С. «Клиническое значение метилирования генов-супрессоров опухолевого роста при патологических процессах эндометрия у женщин репродуктивного возраста»: диссертация кандидата мед. наук, 2011г.


75. Гергова М.М. Микросателлитная нестабильность в опухолях яичников: частота и клинико-морфологические особенности. : диссертация кандидата мед. наук, 2009г.


76. Имянитов Е.В., Молекулярная диагностика в онкологии. //Молекулярная биология, 2008, Т. 42, № 5, С. 772–785.


77. Имянитов Е.Н. Скрининг для лиц с наследственной предрасположенностью к раку. //Практическая Онкология Т.11, -№ 2, 1-14. - 2010 г.1-14.